Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma

Clinical Orthopaedics and Related Research

Volumn 466, Issue 6, 2008, Pages 1285-1291

  Sorenson, Brent S ^a   Banton, Kaysie L ^a   Frykman, Natalie L ^a   Leonard, Arnold S ^a   Saltzman, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDIAN INK; INTERLEUKIN 2; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL POPULATION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; LUNG METASTASIS; LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE TUMOR; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; LUNG TUMOR; METASTASIS; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; OSTEOSARCOMA; SALMONELLA TYPHIMURIUM;

EID: 44949245025     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-008-0243-2     Document Type: Conference Paper

References (38)

1. Barnett SJ, Soto LJ 3rd, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA. Attenuated salmonella typhimurium invades and decreases tumor burden in neuroblastoma. J Pediatr Surg. 2005;40:993-997; discussion 997-998.
2. Bermudes D, Low B, Pawelek J. Tumor-targeted salmonella. highly selective delivery vectors. Adv Exp Med Biol. 2000;465:57-63.
3. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of salmonella typhimurium. J Infect Dis. 2000;181:1996-2002.
4. Curtiss R 3rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987;55:3035-3043.
5. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203-210.
6. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 2005;16:937-946.
7. Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells CL, Sielaff TD. Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated salmonella typhimurium and are associated with reduced tumor in murine liver cancer. J Surg Res. 2002;107:101-107.
8. Feltis BA, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD. Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum. 2002;45:1023-1028.
9. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292-315.
10. Foster L, Dall GF, Reid R, Wallace WH, Porter DE. Twentieth-century survival from osteosarcoma in childhood: Trends from 1933 to 2004. J Bone Joint Surg Br. 2007;89:1234-1238.
11. Harting MT, Blakely ML, Jaffe N, Cox CS Jr, Hayes-Jordan A, Benjamin RS, Raymond AK, Andrassy RJ, Lally KP. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41:194-199.
12. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000;18:261-271.
13. Lewis VO. What's new in musculoskeletal oncology. J Bone Joint Surg Am. 2007;89:1399-1407.
14. Link MP, Gebhardt MC, Meyers PA, Pizzo PA, Poplack DG. Osteosarcoma. In: Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1051-1089.
15. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA. 2007;104:12879-12883.
16. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423-436.
17. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA. 2003;100:8850-8855.
18. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-441.
19. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol. 2004;16:120-125.
20. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
21. Nakayama K., Kelly S.M., Curtiss R. III. Construction of an ASD+ expression cloning vector: Stable maintenance and high level expression of cloned genes in a salmonella vaccine strain. Nature Biotechnology. 1988;6:693-697.
22. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. 2001;61:6178-6184.
23. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jager E, Nomura H, Kondo S, Tawara I, Kato T, Shiku H, Old LJ, Galan JE, Gnjatic S. In vivo antigen delivery by a salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116:1946-1954.
24. Pawelek JM, Low KB, Bermudes D. Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537-4544.
25. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988;208:121-135.
26. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-84; discussion 484-5.
27. Saltzman DA, Heise CP, Hasz DE, Zebede M, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Attenuated salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother Radiopharm. 1996;11:145-153.
28. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Patterns of hepatic and splenic colonization by an attenuated strain of salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. Cancer Biother Radiopharm. 1997;12:37-45.
29. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Vigdorovich V, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM. Antitumor mechanisms of attenuated salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J Pediatr Surg. 1997;32:301-306.
30. Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, Sovinz P, Moser A, Schwantzer G, Urban C. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol. 2005;16:1199-1206.
31. Seibel NL, Krailo M, Chen Z, Healey J, Breitfeld PP, Drachtman R, Greffe B, Nachman J, Nadel H, Sato JK, Meyers PA, Reaman GH. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's cancer group (CCG) 7943. Cancer. 2007;109:1646-1653.
32. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood. 1993;81:1414-1423.
33. Soto LJ 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA. Attenuated salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg. 2003;38:1075-1079.
34. Soto LJ 3rd, Sorenson BS, Nelson BW, Solis SJ, Leonard AS, Saltzman DA. Preferential proliferation of attenuated salmonella typhimurium within neuroblastoma. J Pediatr Surg. 2004;39:937-40; discussion 937-40.
35. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20:142-152.
36. Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 2003;10:755-763.
37. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: The japanese musculoskeletal oncology group study. J Clin Oncol. 2002;20:3470-3477.
38. Xu C, Li ZS, Du YQ, Gong YF, Yang H, Sun B, Jin J. Construction of recombinant attenuated salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World J Gastroenterol. 2007;13:939-944.